A Study With Tepezza in Patients With Diffuse Cutaneous Systemic Sclerosis (Dcssc)
ClinicalTrials.gov NCT04478994
Research payments
$461,535
Through program year 2023, $461,535 in research payments was reported against A Study With Tepezza in Patients With Diffuse Cutaneous Systemic Sclerosis (Dcssc), across 23 payments, paid by Horizon Therapeutics plc.
- Paid by
- Horizon Therapeutics plc
- ClinicalTrials.gov
- NCT04478994
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $88,966 | 7 |
| 2022 | Research | $251,097 | 7 |
| 2021 | Research | $90,572 | 7 |
| 2020 | Research | $30,900 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Daniel Furst Los Angeles, CA Named on 4 payments
- M Kahaleh Toledo, OH Named on 4 payments
- Suzanne Kafaja Los Angeles, CA Named on 3 payments
- Soumya Chatterjee Cleveland, OH Named on 3 payments
- Monique Hinchcliff North Haven, CT Named on 3 payments
- Maureen Mayes Houston, TX Named on 2 payments
- Laura Hummers Baltimore, MD Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.